The Danish drugmaker had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026. The active ...
Mounjaro, manufactured by Lilly, may have emerged as the newest and most effective treatment option after a victory over Novo Nordisk’s Ozempic in clinical trials. For some patients, injectables ...
Eli Lilly (LLY) stock in focus as the company launches its weight loss therapy Mounjaro in India, beating its rival Novo Nordisk (NVO). Read more here.
Lilly reported earlier this month that its revenue in the latest fiscal quarter jumped 45% with its new products contributing more than $3.1 billion, driven mainly by strong demand for Mounjaro ...
In February last year, CEO David Ricks told Reuters that Lilly expects to launch Mounjaro in India as early as 2025. Mounjaro, chemically known as tirzepatide, is currently sold in the UK and ...
Eli Lilly's weight-loss drugs include Mounjaro and Zepbound.Sandy Huffaker for The Washington Post/Getty Images Weight-loss drugs such as Ozempic and Zepbound cost $900 to $1,500 for a month's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback